ScienceTechyNews: NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma

6:46 AM
Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.

by

Post a Comment

No comments

Subscribe to: Post Comments ( Atom )
Powered by Blogger.